Hadlima® PushTouch®

INN: adalimumab

Approved for use in:

Crohn’s Disease (moderate-severe)
Ulcerative Colitis (moderate-severe)

Type/Class

Biosimilar

Delivery Route

Subcutaneous Injection

Health Canada Approval

2019

Storage

Refrigerate between 2 and 8°C, do not freeze, keep in original carton to protect from light, may be stored at room temperature (up to 25°C) for a single period (length of which varies depending on dosage).

Use in Older Adults (65+)

May be used, please consult your doctor.

Pregnancy Indication

No pattern of major birth defects has been observed; infants may be at increased risk for infection.

Breastfeeding Indication

Low exposure levels due to large molecule size and degradation by GI tract.

Pediatric Indication

Not authorized for pediatric IBD patients.

Learn More

View the Hadlima® PushTouch® product monograph.